Crossmark

Increased Patient’s Risk Associated with the Canadian Bioequivalence Guidance Due to Outlier Removal

Published Online: 2021-10-30

Published Print: 2022-01

Authors

Fuglsang, Anders https://orcid.org/0000-0002-6733-2187
License Information

Text and Data Mining valid from 2021-10-30

Version of Record valid from 2021-10-30
More Information

Article History

Received: 13 June 2021

Accepted: 24 September 2021

First Online: 30 October 2021

Declarations

:

: The author is a consultant. Present and former clients include pharmacopeias, agencies, the World Health Organization, and private companies. This paper expresses no opinion or inference about agencies, organizations, companies, political parties, or medicinal products. The author declares no conflict of interest.

Document is current